Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06864988 · ClinicalTrials.gov registry record · Phase 3
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3 study of Macular Neovascularization Secondary to Age-Related Macular Degeneration, sponsored by 4D Molecular Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT06864988: Recruiting Phase 3 study of Macular Neovascularization Secondary to Age-Related Macular Degeneration, sponsored by 4D Molecular Therapeutics.
NCT06864988 is a Phase 3 study of Macular Neovascularization Secondary to Age-Related Macular Degeneration that is actively recruiting participants, run by 4D Molecular Therapeutics. The registered enrollment target is 480 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06864988, a Phase 3 study of Macular Neovascularization Secondary to Age-Related Macular Degeneration, is actively recruiting participants, sponsored by 4D Molecular Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Conditions Studied
Interventions
- BIOLOGICAL 4D-150 IVT (3E10 vg/eye)
- BIOLOGICAL EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Study Locations (20)
California
- California Retina Consultants - Bakersfield
- Retina Vitreous Associates Medical Group - Beverly Hills
- The Retina Partners - Encino
- Retina Associates of Southern California - Huntington Beach
- Loma Linda University Faculty Medical Clinics - Loma Linda
- Jules Stein Eye Institute - Los Angeles
- Northern California Retina Vitreous Associates - Mountain View
- Gavin Herbert Eye Institute - Orange
- Retina Consultants of San Diego - Poway
- Kaiser Permanente-Riverside Medical Center - Riverside
- Retinal Consultants Medical Group Inc - Sacramento
- Retinal Consultants Medical Group Inc - Sacramento
- Orange County Retina Medical Group - Santa Ana
- California Retina Consultants - Santa Barbara - Santa Barbara
- Bay Area Retina Associates - Walnut Creek
Arizona
- Barnet Dulaney Perkins Eye Center - Phoenix
- Retinal Research Institute, LLC - Scottsdale
Colorado
- University of Colorado, Denver - Aurora
- Retina Consultants of Southern Colorado - Colorado Springs
Arkansas
- Retina Partners of Northwest Arkansas - Springdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
What NCT06864988 shows while recruiting
NCT06864988 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower).
The record links to 1 condition, with Macular Neovascularization Secondary to Age-Related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which 4D-150 IVT (3E10 vg/eye) is the first listed.
NCT06864988 names 20 study sites across 4 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT06864988 about?
NCT06864988 is a clinical study titled "4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration". A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
What is the current status of trial NCT06864988?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-03-03. Estimated completion is 2028-06.
What conditions does trial NCT06864988 study?
This clinical trial studies the following conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration.
What interventions are being tested in trial NCT06864988?
The interventions under investigation include: 4D-150 IVT (3E10 vg/eye) (BIOLOGICAL), EYLEA® (aflibercept) Injection 2 mg (0.05mL) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06864988?
This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06864988 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06864988's enrollment target sits among peer trials
480 792nd of 2000 higher than 1,198 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI